

06/01/01
11046 U.S. PTO
09/872127

DE-64-01

A

Attorney Docket No.: 5776.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Commissioner for Patents
Washington, DC 20231

Express Mail Label No. EL 564769316US
Date of Deposit June 1, 2001

Sir:

This is a request for filing a patent application under 37 C.F.R. 1.53(b) of

Applicant(s): Hansen et al.

Title: Use of N-Substituted Azaheterocyclic Compounds for the Manufacture of
a Pharmaceutical Composition for the Treatment of Indications Related to
Angiogenesis

109 pages of specification 1 page of abstract

3 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee:	\$710.00
Total Claims: $34 - 20 = 14 \times 18 =$	\$252.00
Independent Claims: $1 - 3 = 0 \times 80 =$	\$0
Total Fee:	\$962.00

Priority of Danish application no. PA 1998 01586 filed on December 2, 1998 is
claimed under 35 U.S.C. 119. A certified copy is submitted herewith.

Priority of U.S. provisional application no. 60/111,445 filed on December 8, 1998 is
claimed under 35 U.S.C. 119.


The benefit of application no. PCT/DK99/00671 filed on December 1, 1999 in the
PCT is claimed under 35 U.S.C. 120.

Address all future communications to Reza Green, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$962, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: June 1, 2001



Reza Green, Reg. No. 38,475
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
EXPRESS MAIL CERTIFICATE**

Box Patent Application
Commissioner for Patents
Washington, DC 20231

Re: U.S. Patent Application for

Title: Use of N-Substituted Azaheterocyclic Compounds for the
Manufacture of a Pharmaceutical Composition for the Treatment of
Indications Related to Angiogenesis

Applicants: Hansen et al.

Sir:

Express Mail Label No. EL 564769316US

Date of Deposit: June 1, 2001

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Unexecuted Combined Declaration and Power of Attorney
4. Certified Copy of Priority Application
5. Information Disclosure Statement
6. Form PTO-1449
7. Copy of References
8. Preliminary Amendment

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, DC 20231.

Carol McFarlane-Fishberg

(Name of person mailing paper(s) or fee)

Carol McFarlane-Fishberg

(Signature of person mailing paper(s) or fee)

Mailing Address:

Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10017
(212) 867-0123



23650

PATENT TRADEMARK OFFICE